Navigation Links
BiovaxID?yields 89 percent survival in patients with aggressive non-Hodgkins

Accentia Biopharmaceuticals, Inc. report follow-up data to a Phase 2 trial conducted by the National Cancer Institute (NCI) that shows Biovest's BiovaxID yielded an 89% survival rate in mantle cell lymphoma patients.

The median follow-up was 3.8 years. Historically, patients with this type of lymphoma only have had a 50% chance of surviving 3 years and 20% chance of surviving 5 years. BiovaxID, an investigational personalized anti-cancer vaccine, stimulates the immune system to seek out and destroy tumor cells. The data were published in a recent edition of Nature Medicine (Nat Med.2005; 11(9):986-91).

In this single-arm, open-label Phase 2 clinical study, patients with untreated mantle cell non-Hodgkin's lymphoma (NHL) were administered six cycles of dose-adjusted EPOCH-R, a chemotherapy regimen that includes Rituxan® (rituximab). Of the 26 patients in the study, 23 received vaccinations with BiovaxID commencing at least three months after completing their last chemotherapy and Rituxan treatments. Upon the 46-month (3.8-year) follow-up, the overall survival rate was 89%. This study showed that, despite an almost complete depletion of normal B-cell lymphocytes due to EPOCH-R therapy, BiovaxID did induce anti-tumor T-cell lymphocyte responses in most patients. Depletion of normal B-cell lymphocytes is a consequence of the combination of chemotherapy and Rituxan, but not of BiovaxID therapy. Thus, "it is justifiable to administer vaccines in the setting of B-cell depletion, but vaccine boosts after B-cell recovery may be necessary for optimal humoral responses," concluded the investigators.

Lymphocytes are a type of white blood cell. There are two types of lymphocytes: B-cell lymphocytes, which produce antibodies ("humoral" immunity) in response to immune stimulation; and T-cell lymphocytes, which mediate cell responses to immune stimulation ("cellular" immunity). B-cell lymphocytes can undergo malignant transformation to become non-Hogkins lymphoma, multiple myeloma or chronic lymphocytic leukemia.

"This is the first human cancer vaccine study to see T-cell responses in the absence of B-cells," said the study's first author, Sattva Neelapu, M.D., Assistant Professor in the Department of Lymphoma at the University of Texas M. D. Anderson Cancer Center. "This paves the way to use vaccines in a number of hematological cancers that are treated by eliminating diseased B-cells."

Biovest is now enrolling patients in a pivotal Phase 3 trial to test BiovaxID against follicular non-Hodgkin's lymphoma (NHL). Follicular NHL is an indolent (slow-growing) form of lymphoma not considered curable with existing therapies. The impressive findings from the Phase 2 clinical trial using BiovaxID in mantle cell lymphoma suggest the vaccine could potentially be used to treat other types of NHL, in addition to follicular NHL.


'"/>

Source:The Investor Relations Group


Related biology news :

1. Hunger in America rises by 43 percent over last five years
2. Method slashes quantum dot costs by 80 percent
3. Hepatitis B accounts for 40 percent of missing Asian women
4. Vaccine provides 100 percent protection against avian flu virus in animal study
5. Oceans are 70 percent shark free
6. St. Jude projects 90 percent cure rate for ALL
7. Biofuels can replace about 30 percent of fuel needs with significant research and policy effort
8. Psychotropic drug prescriptions for teens surge 250 percent over 7 year period
9. Just the expectation of a mirthful laughter experience boosts endorphins 27 percent, HGH 87 percent
10. Septum keeps neurons in synch, can reduce epileptic seizures by 90 percent
11. One therapeutic dose of radiation causes 30 percent spongy bone loss in mice
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/3/2016)... --> --> Fourth quarter 2015:   ... fourth quarter of 2014. Gross margin was 46% (32). ... Earnings per share increased to SEK 6.39 (loss: 0.49). Cash ... --> --> January to December ... 1,142% compared with 2014. Gross margin was 43% (31). ...
(Date:2/2/2016)... YORK , Feb. 2, 2016 ... of the bioinformatic market by reviewing the recent ... enabled tools that drive the field forward. Includes ... to: Identify the challenges and opportunities that ... providers and software solution developers, as well as ...
(Date:2/1/2016)... -- Rising sales of consumer electronics coupled ... gesture control market size through ... electronics coupled with new technological advancements to drive global ... through 2020   --> Rising ... to drive global touchfree intuitive gesture control market ...
Breaking Biology News(10 mins):
(Date:2/10/2016)... ... February 10, 2016 , ... HOLLOWAY AMERICA, a leading custom ... Rocky Mountain Chapter 21st Annual Vendor Exhibition on Thursday, February 18, 2016. The ... for its annual event, which will run from 3:00 p.m. - 8:30 p.m. ...
(Date:2/10/2016)... (PRWEB) , ... February 10, 2016 , ... ... expansion to their comprehensive training and support program, Sonalink™ remote monitoring. The inaugural ... procedures performed on Friday, February 5th, connecting Dr. Samuel Peretsman to a HIFU ...
(Date:2/10/2016)... (PRWEB) , ... February 10, 2016 , ... ... now available on Microsoft Azure. On Azure, Arvados provides capabilities for managing and ... clear demand for Microsoft Azure from major institutions collecting and analyzing genomic data,” ...
(Date:2/10/2016)... ... February 10, 2016 , ... Cenna Bioscience Inc., an emerging biopharmaceutical ... Alzheimer’s disease, announced today it has been selected to present at the Cavendish Global ... Palm Beach, Florida. The purpose of the Forum is to help family offices ...
Breaking Biology Technology: